March 22nd 2023
Patients with metastatic or recurrent locally advanced Merkel cell carcinoma can now receive treatment with retifanlimab-dlwr following its accelerated approval by the FDA.
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma
This study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.
How the Emergence of Immunotherapy has Impacted Practice Patterns for Treatment and Management of Merkel Cell CarcinomaOctober 19th 2021
A retrospective review identified that clinical practice patterns have changed from 2002 to 2020, with the use of immunotherapy increasing as chemotherapy and radiation therapy use has decreased for patients with Merkel cell carcinoma.
First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal MelanomaFebruary 11th 2021
First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.
FDA Approves Cemiplimab as First Immunotherapy to Treat Patients With Advanced BCCFebruary 9th 2021
The PD-1 inhibitor cemiplimab was granted approval in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom these therapies are not appropriate.
Topical Immunosuppressants Drugs Don’t Increase Risk of Common Skin Cancers, Despite Warning LabelsOctober 5th 2020
A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.
Tavo, Pembrolizumab Combo May Aid in Reducing Remissions in Advanced MelanomaMay 11th 2020
The combination of tavo and pembrolizumab was associated with a higher than anticipated response rate in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes.
Interim Data from KEYNOTE-555 Cohort B Demonstrate Benefit of Alternative Dosing RegimenApril 29th 2020
Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.
AYAs with Certain Cancer Types Saw Improvements in 5-Year Mortality RatesMarch 11th 2020
A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.
Lower Risk of Melanoma Diagnosis and Increased Mortality Following Partner BereavementMarch 5th 2020
These findings highlight the need to raise public awareness of the importance of self-skin examination, and to encourage clinicians to have a lower threshold for undertaking skin examinations in bereaved individuals, according to the researchers.
Circulating Tumor Cells Useful for Identification of Potential Melanoma RelapseFebruary 12th 2020
A recent study determined circulating tumor cells were associated with melanoma relapse, suggesting that this form of liquid biopsy could help identify patients who would benefit from adjuvant therapy.